Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2022 / Jan / Prostate Proteomics
Chromatography Liquid Chromatography Omics Proteomics Sponsored

Prostate Proteomics

How LC-MS/MS analysis is being employed to identify better biomarkers in high-risk prostate cancer patients

01/13/2022 1 min read

Share

Prostate cancer is the fifth leading cause of death among men in western countries, but identifying high-risk individuals with current diagnostic tools is difficult – in part because of the heterogeneous nature of the disease. Although a number of studies have looked at genomic and transcriptomic alterations in prostate cancer, they have not previously been linked to changes at the proteome level.

With a plan to connect the dots, a team of researchers assessed key changes in PCa tissue during tumor progression (1). Using a combination of proteomics and transcriptomics (LC-MS/MS), tissue-microarray generation, and retrospective data analysis, they found that the expression levels of NDUFS1 and ATP50 genes and associated proteins were significantly higher in PCa patients.

Though more work is needed, the researchers believe that the NDUFS1 and ATP50 proteins may serve as novel prognostic markers for the identification of high-risk PCa patients.

Image Credit: National Cancer Institute, National Institutes of Health

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. R Wiebringhaus et al., Cancers, 13, 6036 (2021). DOI:  10.3390/cancers13236036

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.